English | 简体中文 | 繁體中文 | 한국어 | 日本語
2021年12月3日 15時00分 JST
Share:
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
- Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily
- PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant
- Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally
- One of the few companies in Singapore with proprietary technology in testing

シンガポール, 2021年12月3日 - (JCN Newswire) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.

Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, "As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.

With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."

In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.

The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.

This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.

Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.

About Acumen Diagnostics Pte. Ltd.

Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.

Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more information, please visit the company website at www.acumen-research.com.

For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008, query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166, wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707, derek@waterbrooks.com.sg

トピック: Press release summary
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
CleverTap bags ten prestigious awards at the 2024 Stevie Awards  
Apr 16, 2024 20:00 HKT/SGT
LEXUS、ミラノデザインウィーク2024に出展 
Apr 16, 2024 18:00 HKT/SGT
三菱商事、米国ルイジアナ州におけるDACプロジェクトへの参画について 
Apr 16, 2024 14:00 HKT/SGT
NEC、SBTiからNet-Zero目標の認定を取得 
Apr 16, 2024 14:00 HKT/SGT
「LEXUS OVERTRAIL CAMP 2024」を開催 
Apr 15, 2024 13:30 HKT/SGT
InnoEX promotes Hong Kong as international I&T hub 
Apr 13, 2024 20:00 HKT/SGT
三菱重工航空エンジン、航空エンジン向け燃焼器製造の「MHIAEL長崎工場」2期棟を竣工 
Apr 12, 2024 08:00 HKT/SGT
FBS Releases a Major Update to Mobile App: Everything Is Now in Users' Smartphone 
Apr 11, 2024 23:08 HKT/SGT
Atlas Lithium、三井物産から3,000万米ドルの戦略的投資およびオフテイク契約を獲得 
Apr 11, 2024 22:00 HKT/SGT
WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain 
Apr 9, 2024 19:03 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575